A simple and elegant political solution for American Cannabis.
A simple and elegant political solution for American Cannabis.
There are 37 states and 4 U.S. territories with medical or hybrid adult use cannabis programs.
Schedule VI is a proposed new schedule designed to preserve their rights to control & regulate marijuana a.k.a. cannabis.
In October 2022, President Biden indicated he is interested in marijuana reform. Schedule 6 is designed to be a part of the solution.
State Ecosystem + Local Industry
- Regulating cannabis exclusively at the State or Territorial level would ensure safety standards while protecting existing small business ecosystems
- Removing Cannabis from Schedule I of the Controlled Substances Act only for legal cannabis states & territories would resolve the erroneous application of the 280E tax code
- Access to traditional banking & merchant services as well as American stock exchanges would be normalized with a new rescheduling
- Designating Cannabis as Schedule VI allows universities & research institutes that receive federal funding to legally conduct studies around the medical uses of cannabinoids & terpenes using the existing State & Territorial supply chain
- There is nothing more equitable for over three million patients and an industry that employs over half a million Americans than equal treatment by federal agencies including the Internal Revenue Service, Small Business Administration, and the Securities Exchange Commission
Patient + Consumer
- Schedule VI solves a litany of problems for over three million American medical cannabis patients who cannot utilize Health Savings & Flexible Spending Accounts for their medicine
- Rescheduling to state control allows veterans access to a diverse set of cannabis products to mitigate the effects of Post Traumatic Stress Disorder
- Registered patients who use medical cannabis shall not be subjected to additional federal taxes while maintaining their Second Amendment rights
Controlled Substances Act: Schedules I - V
(1) SCHEDULE I.—
(A) The drug or other substance has a high potential for abuse.
(B) The drug or other substance has no currently accepted medical use in treatment in the United States.
(C) There is a lack of accepted safety for use of the drug or other substance under medical supervision.
(2) SCHEDULE II.—
(A) The drug or other substance has a high potential for abuse.
(B) The drug or other substance has a currently accepted medical use in treatment in the United States or a currently accepted medical use with severe restrictions.
(C) Abuse of the drug or other substances may lead to severe psychological or physical dependence.
(3) SCHEDULE III.—
(A) The drug or other substance has a potential for abuse less than the drugs or other substances in schedules I and II.
(B) The drug or other substance has a currently accepted medical use in treatment in the United States.
(C) Abuse of the drug or other substance may lead to moderate or low physical dependence or high psychological dependence.
4) SCHEDULE IV.—
(A) The drug or other substance has a lowpotential for abuse relative to the drugs or other substances in schedule III.
(B) The drug or other substance has a currently accepted medical use in treatment in the United States.
(C) Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule III.
5) SCHEDULE V.—
(A) The drug or other substance has a low potential for abuse relative to the drugs or other substances in schedule IV.
(B) The drug or other substance has a currently accepted medical use in treatment in the United States.
(C) Abuse of the drug or other substance may lead to limited physical dependence or psychological dependence relative to the drugs or other substances in schedule IV.
Although the States Reform Act (SRA) is good policy, we do not believe that the SRA or the Cannabis Opportunity & Administration Act (CAOA) have a significant chance of passage in the coming months & years.
Schedule VI (6) is a small update to the Controlled Substances Act that includes Safe banking, Fair Taxation, Consumer Protection and Health
DRAFT TEXT: PROPOSED Schedule VI Language
(6) Schedule VI.-
(A) The drug or other substance is listed in Schedule I.
(B) The drug or other substance is subject to some degree of abuse and has a currently accepted medical use in treatment or is restricted for Sale to Adults over the age of 21 in the States of Alabama, Alaska, Arizona, Arkansas, California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Iowa, Louisiana, Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nevada, New Hampshire, New Jersey, New Mexico, New York, North Dakota, Ohio, Oklahoma, Oregon, Pennsylvania, Rhode Island, Utah, Vermont, Virginia, Washington, West Virginia, the District of Columbia, the Commonwealth of the Northern Mariana Islands, the United States Virgin Islands, Guam, or Puerto Rico.
(C) Drugs grown or manufactured for intrastate Commerce shall be regulated exclusively by the States. All United States Codes, Internal Revenue Codes and any federal agency rules shall be applied exclusively using this schedule for licensed producers of the drug in the States and Territories listed in (B). Licensed producers shall be defined according to the statutes or codes of the States and Territories listed in (B).
(D) Drug regulation and restriction is governed by each State or Territory listed individually in (B). If a State or Territory not listed in (B) legalizes the drug or other substance for medical use in treatment or makes it available for Sale only to adults over the age of 21, the agency regulating the drug in that State or Territory can notify the Attorney General that it is to be added to (B). The Attorney General shall add the State or Territory to (B) within ninety days of notification.